GTBP
Income statement / Annual
Last year (2023), GT Biopharma, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, GT Biopharma, Inc.'s net income was -$7.60 M.
See GT Biopharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$27,000.00 |
$61,000.00 |
Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$4,000.00
|
$7,000.00
|
$2,000.00
|
$1,000.00
|
$2,000.00
|
$57,000.00
|
Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$4,000.00
|
-$7,000.00
|
-$2,000.00
|
-$1,000.00
|
$25,000.00
|
$4,000.00
|
Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0.93
|
0.07
|
Research and Development Expenses |
$6.47 M
|
$8.81 M
|
$9.59 M
|
$485,000.00
|
$1.67 M
|
$9.07 M
|
$1.07 M
|
$975,000.00
|
$1.00 M
|
$0.00
|
General & Administrative Expenses |
$0.00
|
$0.00
|
$47.92 M
|
$6.28 M
|
$9.79 M
|
$12.49 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$7.11 M
|
$12.45 M
|
$47.92 M
|
$6.28 M
|
$9.79 M
|
$12.49 M
|
$134.50 M
|
$8.40 M
|
$7.95 M
|
$2.40 M
|
Other Expenses |
$0.00
|
$0.00
|
-$242,760.00
|
-$12.60 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Operating Expenses |
$13.58 M
|
$21.26 M
|
$57.52 M
|
$6.76 M
|
$11.46 M
|
$21.55 M
|
$135.57 M
|
$9.37 M
|
$8.95 M
|
$2.40 M
|
Cost And Expenses |
$13.58 M
|
$21.26 M
|
$57.52 M
|
$6.76 M
|
$11.46 M
|
$21.55 M
|
$135.57 M
|
$9.37 M
|
$8.95 M
|
$2.46 M
|
Interest Income |
$567,000.00
|
$292,000.00
|
$38,000.00
|
$3,320.00
|
$2,128.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Interest Expense |
$0.00
|
$8,000.00
|
$718,000.00
|
$3.32 M
|
$2.13 M
|
$9.12 M
|
$8.60 M
|
$6.56 M
|
$17.04 M
|
$5.15 M
|
Depreciation & Amortization |
$13.58 M
|
$21.26 M
|
$57.52 M
|
$4,000.00
|
$4,000.00
|
$7,000.00
|
$2,000.00
|
$1,000.00
|
$2,000.00
|
$22,000.00
|
EBITDA |
$5.98 M |
$0.00 |
$0.00 |
-$24.98 M |
-$11.45 M |
-$250.06 M |
-$135.57 M |
-$9.37 M |
-$8.93 M |
-$2.37 M |
EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-330.56
|
-38.92
|
Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-330.63
|
-39.28
|
Total Other Income/Expenses Net |
$5.98 M
|
$373,000.00
|
-$498,000.00
|
-$21.53 M
|
-$22.59 M
|
-$9.12 M
|
-$7.68 M
|
$19.14 M
|
-$12.53 M
|
-$21.11 M
|
Income Before Tax |
-$7.60 M
|
-$20.88 M
|
-$58.01 M
|
-$28.30 M
|
-$38.65 M
|
-$259.19 M
|
-$143.25 M
|
$21.03 M
|
-$32.73 M
|
-$23.49 M
|
Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-1212.07
|
-385.07
|
Income Tax Expense |
$0.00
|
-$381,000.00
|
$680,000.00
|
$3.32 M
|
$2.13 M
|
-$228.52 M
|
$7.68 M
|
-$30.41 M
|
$17.04 M
|
$5.15 M
|
Net Income |
-$7.60 M
|
-$20.50 M
|
-$58.69 M
|
-$31.62 M
|
-$40.78 M
|
-$259.19 M
|
-$143.25 M
|
$21.03 M
|
-$32.73 M
|
-$23.49 M
|
Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-1212.07
|
-385.07
|
EPS |
-5.64 |
-19.3 |
-62.54 |
-216.29 |
-361.49 |
-87.7 |
-145.22 |
4390.11 |
-69629.79 |
-50622.84 |
EPS Diluted |
-5.64 |
-19.3 |
-62.54 |
-216.29 |
-361.49 |
-87.7 |
-145.22 |
4390.11 |
-69629.79 |
-50622.84 |
Weighted Average Shares Out |
$1.35 M
|
$1.06 M
|
$938,520.00
|
$146,172.00
|
$112,798.00
|
$2.96 M
|
$986,419.00
|
$4,791.00
|
$470.00
|
$464.00
|
Weighted Average Shares Out Diluted |
$1.35 M
|
$1.06 M
|
$938,520.00
|
$146,172.00
|
$112,798.00
|
$2.96 M
|
$986,419.00
|
$4,791.00
|
$470.00
|
$464.00
|
Link |
|
|
|
|
|
|
|
|
|
|